Clinical Trial Update: A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy [Phase 4]

View source ↗

Summary

Completed Phase 4 clinical trial evaluating abiraterone acetate in metastatic castration-resistant prostate cancer patients who had a poor response to first-lin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Zytiga (abiraterone acetate)

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Metastatic Castration-Resistant Prostate Cancer | Phase 4 | Status: COMPLETED